Physician profile
Peyton Brouwer
NPI 1164165353
$10,734.84
in general payments reported to CMS, 2019-2025
29 companies · $2,420 in 2025
The $2,420 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $840 · 2023: $4,251 · 2024: $3,224 · 2025: $2,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,115 · Consulting Fee: $675 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,114.59 |
| Consulting Fee | $675.00 |
| Education | $105.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,871.10 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $1,069.64 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $1,042.59 | 2022-2024 | Vtama |
| Abbvie INC. | $876.06 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $656.84 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $638.56 | 2022-2025 | |
| Galderma Laboratories, L.P. | $629.37 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Amgen INC. | $564.10 | 2023-2025 | Otezla, Krystexxa, Otezla |
| Sun Pharmaceutical Industries INC. | $489.65 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $414.03 | 2022-2025 | Jublia, Siliq, Targretin |
| Janssen Biotech, INC. | $357.00 | 2023-2025 | Tremfya |
| Incyte Corporation | $339.25 | 2023-2025 | Opzelura |
| Ucb, INC. | $288.94 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $258.73 | 2022-2025 | Dupixent |
| Organon LLC | $258.58 | 2025 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $239.10 | 2024-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $202.01 | 2023-2025 | |
| Lilly USA, LLC | $99.95 | 2024 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $89.95 | 2023 | |
| Pfizer INC. | $78.12 | 2023 | |
| Journey Medical Corporation | $51.60 | 2022-2023 | |
| Almirall LLC | $49.69 | 2023-2024 | Seysara |
| Biofrontera INC. | $38.76 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boston Scientific Corporation | $35.40 | 2025 | Axonics |
| Novartis Pharmaceuticals Corporation | $24.49 | 2024 | |
| Verrica Pharmaceuticals INC. | $22.36 | 2025 | Ycanth |
| Botanix Sb INC | $18.08 | 2025 | Sofdra |
| Lnhc, INC | $15.69 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyton Brouwer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.